Certified Nurse-Midwife Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Diann Burling

Advanced Practice Midwife Albany, GA Certified Nurse-Midwife

NPI 1437671559 CMS profile 11128125

2100 Palmyra Rd, Albany, GA 31701

Open in the dashboard

General payments

$1,861

103 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Diann Burling of Albany, GA is reported in the CMS Open Payments database as having received $1,861 across 103 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Advanced Practice Midwife profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $345 17
2024 General $478 25
2023 General $365 20
2022 General $293 18
2021 General $380 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Diann Burling
  • Advanced Practice Midwife median
  • Middle half of Advanced Practice Midwife
  • National median

In program year 2025, general payments to Diann Burling were reported at $345. Among 4,127 Advanced Practice Midwife profiles paid that year, the median was $71 and the middle half received between $28 and $161.

Show as a table
Year Diann Burling Advanced Practice Midwife median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $380 $57 $22–$142 $132
2022 $293 $61 $23–$157 $149
2023 $365 $68 $26–$167 $160
2024 $478 $63 $25–$142 $164
2025 $345 $71 $28–$161 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $292 17 payments
  2. Amgen Inc. $252 17 payments
  3. Shield Therapeutics Inc $246 12 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $222 12 payments
  5. Evofem Biosciences, Inc. $153 8 payments
  6. Mayne Pharma Inc. $93 4 payments
  7. Astellas Pharma US Inc $93 5 payments
  8. Organon LLC $85 5 payments
  9. Pacira Pharmaceuticals Incorporated $71 3 payments
  10. Lilly USA, LLC $49 3 payments
  11. Other $305 17 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,861 103 payments
Products named General payments · program years 2021–2025
  1. EVENITY $223 15 payments
  2. ACCRUFER $208 10 payments
  3. Mirena $158 8 payments
  4. Phexxi $153 8 payments
  5. ORILISSA $135 8 payments
  6. LILETTA $129 7 payments
  7. ORIAHNN $120 7 payments
  8. Prolia $113 8 payments
  9. Veozah $93 5 payments
  10. Kyleena $88 5 payments
  11. Other $703 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

103 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record